SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by The New England Journal of Medicine ...

The FDA cleared an automated insulin delivery system for use by pregnant women with type 1 diabetes, according to an industry ...

The approval is based on findings from the CIRCUIT trial published in JAMA in October 2025.

Tandem Diabetes Care recently received FDA clearance for its Control-IQ+ automated insulin delivery technology to be used during pregnancies complicated by type 1 diabetes, covering both its t:slim X2 ...

Tandem Diabetes Care has announced that the U.S. Food and Drug Administration (FDA) has cleared Control-IQ+ automated insulin delivery (AID) technology for use in pregnancy complicated by ...

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...

Tandem Diabetes Care Inc.’s Control-IQ+ automated insulin delivery system improved multiple measures of glycemic control in individuals with type 2 diabetes who use insulin, a study presented March 19 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Tandem Mobi Now Compatible with Android Smartphones in U.S. "By expanding to Android, we’re broadening our reach to bring the benefits of Tandem Mobi to even more people living with diabetes," said ...

– Additional data presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes – Results published in NEJM demonstrate significant improvements in time in range ...